Literature DB >> 9352314

Effects of cAMP-phosphodiesterase isozyme inhibitor on cytokine production by lipopolysaccharide-stimulated human peripheral blood mononuclear cells.

T Yoshimura1, C Kurita, T Nagao, E Usami, T Nakao, S Watanabe, J Kobayashi, F Yamazaki, H Tanaka, H Nagai.   

Abstract

1. The effects of cAMP-phosphodiesterase (PDE) isozyme inhibitors on the production of tumor necrosis factor alpha (TNF-alpha), and interleukins 1 beta 8 (IL-1 beta and IL-8) by lipopolysaccharide (LPS)-stimulated human peripheral blood mononuclear cells (PBMC) were evaluated. In addition, we investigated the effects of dibutyryl cAMP (dbcAMP) and beta-adrenergic receptor agonist on the production of these cytokines. 2. Type IV PDE inhibitors were more effective at inhibiting the production of TNF-alpha and IL-1 beta by LPS-stimulated PBMC than a nonselective, type III or type III/IV inhibitor. In contrast, these agents had no effect on IL-8 production. 3. Increasing concentrations of dbcAMP progressively reduced the production of TNF-alpha and IL-1 beta but not IL-8. 4. The addition of beta-agonist increased the inhibitory effect of PDE inhibitors tested on the production of TNF-alpha and IL-1 beta. 5. Type IV PDE inhibitors could be potent pharmacological agents for the treatment of diseases in which TNF-alpha and IL-1 beta are important etiological factors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9352314     DOI: 10.1016/s0306-3623(96)00580-0

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  10 in total

1.  Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats.

Authors:  Han-Ting Zhang; Ying Huang; Kathleen Mishler; Sandra C Roerig; James M O'Donnell
Journal:  Psychopharmacology (Berl)       Date:  2005-09-29       Impact factor: 4.530

2.  Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses.

Authors:  S-L Catherine Jin; Marco Conti
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

3.  Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide.

Authors:  A Buenestado; S Grassin-Delyle; F Guitard; E Naline; C Faisy; D Israël-Biet; E Sage; J F Bellamy; H Tenor; P Devillier
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

4.  The activities of drug inactive ingredients on biological targets.

Authors:  Joshua Pottel; Duncan Armstrong; Ling Zou; Alexander Fekete; Xi-Ping Huang; Hayarpi Torosyan; Dallas Bednarczyk; Steven Whitebread; Barun Bhhatarai; Guiqing Liang; Hong Jin; S Nassir Ghaemi; Samuel Slocum; Katalin V Lukacs; John J Irwin; Ellen L Berg; Kathleen M Giacomini; Bryan L Roth; Brian K Shoichet; Laszlo Urban
Journal:  Science       Date:  2020-07-24       Impact factor: 47.728

5.  The role of adenosine receptors in regulating production of tumour necrosis factor-alpha and chemokines by human lung macrophages.

Authors:  A Buenestado; S Grassin Delyle; I Arnould; F Besnard; E Naline; S Blouquit-Laye; A Chapelier; J F Bellamy; P Devillier
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

Review 6.  Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide.

Authors:  Urs A Boelsterli
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

7.  The long-acting β2 -adrenoceptor agonist olodaterol attenuates pulmonary inflammation.

Authors:  Eva Wex; Ines Kollak; Matthias J Duechs; Emmanuel Naline; Lutz Wollin; Philippe Devillier
Journal:  Br J Pharmacol       Date:  2015-05-12       Impact factor: 8.739

8.  Human lung and monocyte-derived macrophages differ with regard to the effects of β2-adrenoceptor agonists on cytokine release.

Authors:  Tatiana Victoni; Hélène Salvator; Charlotte Abrial; Marion Brollo; Luis Cristovão Sobrino Porto; Vincent Lagente; Emmanuel Naline; Stanislas Grassin-Delyle; Philippe Devillier
Journal:  Respir Res       Date:  2017-06-21

9.  Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma.

Authors:  Amparo Buenestado; Marie-Camille Chaumais; Stanislas Grassin-Delyle; Paul-André Risse; Emmanuel Naline; Elisabeth Longchampt; Hermann Tenor; Philippe Devillier
Journal:  PLoS One       Date:  2013-09-16       Impact factor: 3.240

10.  Cyclic AMP Signaling through Epac Axis Modulates Human Hemogenic Endothelium and Enhances Hematopoietic Cell Generation.

Authors:  Shobhit Saxena; Roger E Rönn; Carolina Guibentif; Roksana Moraghebi; Niels-Bjarne Woods
Journal:  Stem Cell Reports       Date:  2016-04-21       Impact factor: 7.765

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.